Clinical Trials · NCT00499993
Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Ipsen
- Enrollment
- 63
- Start date
- Jan 2001
- Locations
- 24 sites, Italy
- Primary endpoint
- Growth hormone assessment